336
Participants
Start Date
June 28, 2024
Primary Completion Date
February 28, 2026
Study Completion Date
March 31, 2026
Nizaracianine Triflutate
Participants will receive up to 3 intravenous bolus injections with a minimal interval between doses of 60 minutes (surgeon discretion). Dose will be 1.0 or 2.5 mg depending on trial phase.
Placebo Comparator
In Phase 3A only, \~50 subjects will be randomly allocated to receive sugar placebo
RECRUITING
Cedars Sinai Medical Center, Los Angeles
RECRUITING
Board of Trustees of Leland Stanford Junior University, Redwood City
RECRUITING
University of Massachusetts Chan Medical School, Worcester
RECRUITING
University Medical Center Groningen, Groningen
RECRUITING
Martini Hospital, Groningen
RECRUITING
Leiden University Medical Centre (LUMC), Leiden
RECRUITING
Erasmus Medical Centre, Rotterdam
RECRUITING
Isala Zwolle, Zwolle
Collaborators (1)
Leiden University Medical Center
OTHER
Erasmus Medical Center
OTHER
University of Massachusetts Chan Medical School, Worcester
UNKNOWN
Stanford University
OTHER
Cedars-Sinai Medical Center
OTHER
University Medical Center Groningen
OTHER
Martini Hospital Groningen
OTHER
Isala
OTHER
Curadel Surgical Innovations, Inc.
INDUSTRY